NCT05966272View on ClinicalTrials.gov

Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

August 12, 2023

Primary Completion Date

September 24, 2024

Study Completion Date

September 24, 2024

Conditions
Type 2 Diabetes
Interventions
DRUG

HRS9531 injection

single dose

DRUG

HRS9531 injection Placebo

single dose

Trial Locations (1)

250021

Shandong Provincial Hospital, Jinan

All Listed Sponsors
lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT05966272 - Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects | Biotech Hunter | Biotech Hunter